EP0264410A1 - Anti-cold kit, anti-cold preparation and use thereof - Google Patents
Anti-cold kit, anti-cold preparation and use thereofInfo
- Publication number
- EP0264410A1 EP0264410A1 EP87902498A EP87902498A EP0264410A1 EP 0264410 A1 EP0264410 A1 EP 0264410A1 EP 87902498 A EP87902498 A EP 87902498A EP 87902498 A EP87902498 A EP 87902498A EP 0264410 A1 EP0264410 A1 EP 0264410A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- cold
- ascorbate
- dexpanthenol
- preparation
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 61
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 84
- 235000010323 ascorbic acid Nutrition 0.000 claims abstract description 41
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims abstract description 40
- 239000011668 ascorbic acid Substances 0.000 claims abstract description 40
- 235000004866 D-panthenol Nutrition 0.000 claims abstract description 39
- 239000011703 D-panthenol Substances 0.000 claims abstract description 39
- 229960003949 dexpanthenol Drugs 0.000 claims abstract description 39
- 229940072107 ascorbate Drugs 0.000 claims abstract description 36
- 239000007864 aqueous solution Substances 0.000 claims abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000000203 mixture Substances 0.000 claims abstract description 4
- 235000010378 sodium ascorbate Nutrition 0.000 claims description 15
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 claims description 15
- 229960005055 sodium ascorbate Drugs 0.000 claims description 14
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical group [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 6
- 239000000872 buffer Substances 0.000 claims description 6
- 239000003755 preservative agent Substances 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims description 2
- 238000011200 topical administration Methods 0.000 claims 2
- 206010027654 Allergic conditions Diseases 0.000 claims 1
- 239000000243 solution Substances 0.000 description 18
- 238000012360 testing method Methods 0.000 description 13
- 210000001331 nose Anatomy 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 239000000902 placebo Substances 0.000 description 8
- 229940068196 placebo Drugs 0.000 description 8
- 201000009240 nasopharyngitis Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 210000004400 mucous membrane Anatomy 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 241000709661 Enterovirus Species 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- -1 alkali metal ascorbate Chemical class 0.000 description 4
- 229960005070 ascorbic acid Drugs 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 230000001603 reducing effect Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229940100662 nasal drops Drugs 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 229910021607 Silver chloride Inorganic materials 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000000644 isotonic solution Substances 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000033116 oxidation-reduction process Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 150000000994 L-ascorbates Chemical class 0.000 description 1
- 240000004760 Pimpinella anisum Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000004260 Potassium ascorbate Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- QKWNIOMGXBERHJ-RXSVEWSESA-N azane;(2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one Chemical compound N.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QKWNIOMGXBERHJ-RXSVEWSESA-N 0.000 description 1
- 229940002010 banana extract Drugs 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 235000010376 calcium ascorbate Nutrition 0.000 description 1
- 229940047036 calcium ascorbate Drugs 0.000 description 1
- 239000011692 calcium ascorbate Substances 0.000 description 1
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 description 1
- 235000019994 cava Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- SNPLKNRPJHDVJA-UHFFFAOYSA-N dl-panthenol Chemical compound OCC(C)(C)C(O)C(=O)NCCCO SNPLKNRPJHDVJA-UHFFFAOYSA-N 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- DCYOBGZUOMKFPA-UHFFFAOYSA-N iron(2+);iron(3+);octadecacyanide Chemical compound [Fe+2].[Fe+2].[Fe+2].[Fe+3].[Fe+3].[Fe+3].[Fe+3].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] DCYOBGZUOMKFPA-UHFFFAOYSA-N 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical group COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000001139 pH measurement Methods 0.000 description 1
- 210000003254 palate Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000019275 potassium ascorbate Nutrition 0.000 description 1
- 229940017794 potassium ascorbate Drugs 0.000 description 1
- CONVKSGEGAVTMB-RXSVEWSESA-M potassium-L-ascorbate Chemical compound [K+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] CONVKSGEGAVTMB-RXSVEWSESA-M 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 229940056904 zinc ascorbate Drugs 0.000 description 1
- WWRJFSIRMWUMAE-ZZMNMWMASA-L zinc;(2r)-2-[(1s)-1,2-dihydroxyethyl]-3-hydroxy-5-oxo-2h-furan-4-olate Chemical compound [Zn+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] WWRJFSIRMWUMAE-ZZMNMWMASA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
Definitions
- Anti-cold kit anti-cold preparation and use thereof
- Common cold is one of the world's most widespread diseases. In some countries it is estimated that about 15 % of all absence from work due to illness is caused by common cold, and although the disease is not considered to be one of the most dangerous ones, it is in any case among the most expensive for society. It is also often a precursor for other respiratory passage diseases, such as bronchitis and pneumonia.
- about one milliliter of drops according to the invention if taken topically provides 1000 times greater levels of ascorbate in the nose than 15 g vitamin C orally in one dose.
- the synergistic effect of the preparation according to the invention results in a desirable prolonged effect on the mucous membrane.
- an anti-cold preparation which is in the form of a substantially isotonic aqueous solution comprising dexpanthenol and a water-soluble, physiologically acceptable ascorbate. It is a further object of the invention to provide an anti-cold kit which comprises a watersoluble, physiologically acceptable ascorbate and dexpanthenol. Furthermore the invention is directed to the use of said kit for the manufacture of said anti-cold preparation. A further object of the invention is the use of the preparation according to the invention for treatment or prophylaxis of conditions responsive to the disclosed synergistic combination of a watersoluble, physiologically acceptable ascorbate and dexpanthenol.
- a water-soluble, physiologically acceptable ascorbate is e. g. an alkali metal ascorbate , such as sodium or potassium ascorbate, or an ascorbate such as calcium ascorbate, zinc ascorbate or ammonium ascorbate.
- An alkali metal ascorbate is preferred, especially preferred is sodium ascorbate of the formula
- D-panthenol also known as D-panthenol, is (R)-2,4-dihydroxy-N-(3-hydroxypro ⁇ yl)-3,3-dimethylbutaneamide of the formula
- kits and the preparation comprise an ascorbate as defined hereinbefore and dexpanthenol as the essential active ingredients, in a preferred embodiment as their only active ingredients.
- the ascorbate and dexpanthenol should be used in a molar ratio of about 5:1 to 1:5, preferably of about 2:1 to 1:2, most preferably in about the same molar amounts. It is possible to use an excess of one or the other component in the preparation, since the components also separately have a favourable effect on their own.
- the preparation must be essentially isotonic, it must be non-irritating and compatible with the tissue and have a pH close to that which is normally found in the nose (mouth, throat).
- An isotonic solution is generally defined as a solution being isoosmotic with a 0,9 % sodium chloride solution.
- the instant essentially isotonic preparation may be slightly hypertonic, but generally the tonicity of the preparation is equivalent to a 0,9 % sodium chloride solution or in the range of a 0.9 % sodium chloride solution.
- the pH of nasal secretion is slightly alkaline (pH between 8 and 9). Accordingly the pH of the preparation is preferably about neutral, e.g. about pH 6 to 7.
- solutions which comprise about 3 % by weight of dexpanthenol and an equimolar amount of ascorbate.
- a preferred preparation comprises about 3 % by weight of sodium ascorbate and about 3 % by weight of dexpanthenol.
- the preparation may also contain isotonicity or pH regulating additions and acceptable flavouring agents and preserving agents.
- pH-regulating additions are buffers, e.g. borate buffers, or preferably phosphate buffers.
- Suitable preserving agents are e.g. methyl- or propyl-p-hydroxy-benzoate, chlorobutanol or, being preferred, benzalkoniumchloride.
- Flavouring agents or artificial sweeteners may be present, such as banana extract (especially for children), anis, menthol, or pineapple. These ingredients are optional and, if present, are present in small amounts.
- a basic salt such as e.g. sodium carbonate
- a pH of the preparation near to neutral.
- Freshly prepared preparations have a redox potential rH (derived according to Clark's formula) of 15.5 whereas the mucus of the nose has an average rH of 23-24 (For details see example 4). Accordingly the preparation of the present invention lowers the redox potential in the nose which is beneficial in that a lower potential is detrimental to the growing conditions of the common cold viruses.
- R.1 2 % aqueous solution of potassium ferricyanide
- R.2 4 % aqueous solution of ferric chloride.
- the flask was then filled to the mark with distilled water.
- the mixing of R.1 and R.2 forms a brown colour, but the presence of any reducing agent will render the solution blue, due to the formation of the Berlin blue colour.
- the intensity of the blue colour was measured using a Lovibond tintometer (cell width 1/2 inch.) and Table 1 gives the experimental results.
- the measurements were made 3 minutes after adding the reagents.
- the values obtained are in direct proportion to the reducing power of the nose washings and are thus an indication of the activity of the solutions as antioxidants i.e.
- the preparation as a kit of two separate units, wherein one unit contains a dry, water-soluble physiologically acceptable ascorbate, such as sodium ascorbate, suitably in a glass bottle equipped with a pipette.
- a dry, water-soluble physiologically acceptable ascorbate such as sodium ascorbate
- An aqueous solution of dexpanthenol is kept in another unit, such as a glass bottle.
- the contents of the two units are mixed, for instance by pouring an aqueous solution of dexpanthenol into the glass bottle containing the starting ascorbate.
- the amount of starting ascorbate and of dexpanthenol must be adjusted so that the resulting solution becomes essentially isotonic.
- the preparation may also be prepared from a kit comprising calculated weighed amounts of the neat active ingredients, ascorbate and dexpanthenol, without the presence of water.
- This kit will be stable for a prolonged time, and a suitable amount of distilled water is added thereto immediately before use, whereby there is obtained a solution which may be used directly.
- the final preparation may also be kept in frozen condition.
- the new preparation may be used as a prophylactic agent or after a cold has broken out. It is suitably used as a prophylactic agent, for instance after a cold epidemic has broken out, and it will then to a considerable extent prevent those who have been treated with the preparation, from catching a cold.
- the new kit and preparation may be beneficial and/or prophylactic against dust or polluted air, and may be used as an antiallergic or antihistaminic agent, e.g. for mammmals, especially human beings, suffering from hey fever.
- the preparation has been successfully tested on several individuals, who have either not caught a cold even if they have been in an environment with much cold, or who have rapidly recovered after having caught a cold.
- a larger systematic test was carried out in a military camp in which all the voluntary test persons were of approximately the same age and were exposed to approximately the same conditions.
- a group of the test persons received a preparation containing the described components, (see example 1), while another group only received a placebo preparation, in each case about 1 ml (20 to 30 drops) in each nostril about 5 times daily. None of the test persons knew whether they received the placebo preparation or a preparation containing the active components.
- a further testing was carried out mainly at the Training Center of the Royal Norwegian Air Force at Kjevik in Southern Norway and also at the University of Oslo.
- the subjects were asked to apply the nosedrops according to the invention into both nostrils so that they could clearly feel it trickling down the back of the nasal cavity and into the throat.
- a small amount was also sprayed into the mouth cavity, over the palate, and in the throat, so that the mucous membranes of the upper respiratory tract were well moistened with the solution.
- the subjects were asked to report on special forms the effects of the drops.
- the preparation (but not the placebo) was also used as a prophylactic during military manoeuvres in the mountains in the winter of 1985. Although the soldiers slept in snow caves where the temperature was well below freezing point (between -15 and -30°C.), none of the participants developed a cold during the manoevres which lasted for about 12 days. In previous years more than 50 % of the soldiers had developed a cold during same type of manoeouvres.
- the clinical tests give the following results showing the distribution of subjects in the two groups, - the group relative to treatment and the placebo-group - having reference to the category and results of treatment and showing the significant level of difference between the two groups:
- Example 1 3.16 g (0.0155 moles) of dexpanthenol are dissolved in 100 ml distilled water, and the solution is filled into a 100 ml bottle. In another 100 ml bottle 3.05 g (0.0155 moles) sodium ascorbate are charged. The content in the two bottles is stable for a long time.* Immediately before use the dexpanthenol solution is filled into the bottle containing the solid sodium ascorbate which dissolves. The resulting solution represents an essentially isotonic preparation ready for use.
- Example 2 The same amounts as above of the two starting materials are mixed and kept in a sterile bottle. The same amount (100 ml) of sterile, distilled water is added immediately before use and results in a clear solution.
- Example 3 After mixing 0.9 g sodium ascorbate (dry substance) with the attached 30 ml solution of stabilized buffered dexpanthenol in water the final mixture has the following composition:
- This preparation of 30 ml has a pH of 6.5. Stability is guaranteed for 1 week.
- E ref standard potential of reference electrode.
- E N value of electrode slope VS temperature. Nernst potential.
- MV Millivolt measured at reference (Platinum/silver chloride) electrode.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
- Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NO861585 | 1986-04-22 | ||
NO861585A NO161779C (no) | 1986-04-22 | 1986-04-22 | Fremgangsmaate for fremstilling av et antiforkjoelsespreparat. |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0264410A1 true EP0264410A1 (en) | 1988-04-27 |
Family
ID=19888883
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP87902498A Withdrawn EP0264410A1 (en) | 1986-04-22 | 1987-04-15 | Anti-cold kit, anti-cold preparation and use thereof |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP0264410A1 (fi) |
JP (1) | JPS63503068A (fi) |
KR (1) | KR880701100A (fi) |
AU (1) | AU7239987A (fi) |
DE (1) | DE3790208T1 (fi) |
DK (1) | DK674587D0 (fi) |
FI (1) | FI875624A0 (fi) |
GB (1) | GB2198946A (fi) |
IL (1) | IL82281A0 (fi) |
NL (1) | NL8720186A (fi) |
NO (1) | NO161779C (fi) |
SE (1) | SE8705060D0 (fi) |
WO (1) | WO1987006465A1 (fi) |
ZA (1) | ZA872824B (fi) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0644754A4 (en) * | 1990-12-06 | 1995-12-27 | Leslie Binshyang Soong | SUBSTANCE WHICH CAN STOP BLEEDING IN SURGICAL, MEDICAL AND DENTAL APPLICATIONS / SUBSTANCE IN THE POWDER FORM 001 WHICH CAN STOP BLEEDING IN SURGERY, POST-SURGERY, MEDICINE, DENTISTRY OR ANY CAUSED HARMONIES. |
US5935584A (en) * | 1994-01-13 | 1999-08-10 | Elizabeth Arden Company | Vitamin C delivery system |
EP0729746A1 (en) * | 1995-02-28 | 1996-09-04 | Unilever Plc | Vitamin C delivery system |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4940728A (en) * | 1985-05-17 | 1990-07-10 | Postley John E | Treatment for sino-nasal congestion |
-
1986
- 1986-04-22 NO NO861585A patent/NO161779C/no unknown
-
1987
- 1987-04-15 NL NL8720186A patent/NL8720186A/nl unknown
- 1987-04-15 WO PCT/EP1987/000203 patent/WO1987006465A1/en not_active Application Discontinuation
- 1987-04-15 EP EP87902498A patent/EP0264410A1/en not_active Withdrawn
- 1987-04-15 GB GB08729227A patent/GB2198946A/en active Pending
- 1987-04-15 AU AU72399/87A patent/AU7239987A/en not_active Abandoned
- 1987-04-15 DE DE19873790208 patent/DE3790208T1/de not_active Withdrawn
- 1987-04-15 JP JP62502527A patent/JPS63503068A/ja active Pending
- 1987-04-15 KR KR1019870701206A patent/KR880701100A/ko not_active Application Discontinuation
- 1987-04-22 ZA ZA872824A patent/ZA872824B/xx unknown
- 1987-04-22 IL IL82281A patent/IL82281A0/xx unknown
- 1987-12-18 SE SE8705060A patent/SE8705060D0/xx not_active Application Discontinuation
- 1987-12-21 FI FI875624A patent/FI875624A0/fi not_active Application Discontinuation
- 1987-12-21 DK DK674587A patent/DK674587D0/da not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
See references of WO8706465A1 * |
Also Published As
Publication number | Publication date |
---|---|
GB8729227D0 (en) | 1988-02-17 |
FI875624A (fi) | 1987-12-21 |
JPS63503068A (ja) | 1988-11-10 |
SE8705060L (sv) | 1987-12-18 |
NO861585L (no) | 1987-10-23 |
AU7239987A (en) | 1987-11-24 |
DK674587A (da) | 1987-12-21 |
DE3790208T1 (fi) | 1988-04-21 |
NO161779B (no) | 1989-06-19 |
SE8705060D0 (sv) | 1987-12-18 |
KR880701100A (ko) | 1988-07-25 |
ZA872824B (en) | 1987-11-25 |
NO161779C (no) | 1989-10-04 |
NL8720186A (nl) | 1988-03-01 |
GB2198946A (en) | 1988-06-29 |
DK674587D0 (da) | 1987-12-21 |
FI875624A0 (fi) | 1987-12-21 |
WO1987006465A1 (en) | 1987-11-05 |
IL82281A0 (en) | 1987-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Rosenberg et al. | Day‐long reduction of oral malodor by a two‐phase oil: water mouthrinse as compared to chlorhexidine and placebo rinses | |
Campbell et al. | Motor neurone disease and exposure to lead | |
Ekstrand et al. | Fluoride pharmacokinetics in infancy | |
Valdes-Dapena et al. | Boric acid poisoning: Three fatal cases with pancreatic inclusions and a review of the literature | |
Chicharro et al. | Trace elements and electrolytes in human resting mixed saliva after exercise. | |
Newbrun | Topical fluoride therapy: discussion of some aspects of toxicology, safety, and efficacy | |
CN112826751B (zh) | 一种增强氟活性的抗敏感牙膏 | |
Berchtold et al. | Effects of a biguanide (metformin) on vitamin B12 and folic acid absorption and intestinal enzyme activities | |
CN112220699A (zh) | 口腔护理组合物 | |
US20060239938A1 (en) | Dental balm and method of prevention of damage to teeth | |
EP0264410A1 (en) | Anti-cold kit, anti-cold preparation and use thereof | |
JP2005501068A (ja) | 特に眼科分野における適用のための外傷および損傷の治癒および/または修復のための治療に適したアミノ酸組成物 | |
US4419341A (en) | Drug for treatment of dental caries | |
US4346082A (en) | Method of employing therapeutic composition comprising ammonium or substituted ammonium compounds for treatment of alcoholism | |
Rigas et al. | Longitudinal distribution of ozone absorption in the lung: Effects of nitrogen dioxide, sulfur dioxide, and ozone exposures | |
CN110151574A (zh) | 一种稳定性二氧化氯含漱液及其制备方法 | |
Bourinbaiar et al. | Synergistic effect of gramicidin and EDTA in inhibiting sperm motility and cervical mucus penetration in vitro | |
Warming-Larsen et al. | The influence of ACTH on the sodium and potassium concentrations of human saliva | |
Kaur et al. | The immediate Term effect of chewing commercially available Meswak (Salvadora persica) on levels of Calcium, Chloride, Phosphate and Thiocyanate in whole saliva | |
Fahmy | Oral and dental affections in mercury‐exposed workers | |
Mertz-Nielsen et al. | Reappraisal of bicarbonate secretion by the human oesophagus. | |
CN108853487A (zh) | 一种治疗口腔溃疡的口腔护理液及其制备方法 | |
Petrović et al. | Aerosol inhalation of CaNa2E. DTA (mosatil) by workers constantly exposed to lead poisoning | |
Bayou | Role Of Fluoride In Dental Health | |
Chen et al. | Lack of significant effect of coffee and caffeine on fluoride metabolism in rats |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19871110 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): BE FR IT LU |
|
RAP3 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BRAENDEN, OLAV J. |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 19890817 |